SCHEMBL6135073

SCHEMBL6135073

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)/C=C/c3ccccc3)cc2c1Cc1ccc(Br)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.41
PTGS2 P35354 1/20 0.39
TP53 P04637 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CXCR2 P25025 1/20 0.38
PTPN5 P54829 1/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
POLB P06746 2/20 0.37
HDAC3 O15379 3/20 0.36
HDAC4 P56524 3/20 0.36
HDAC1 Q13547 3/20 0.36
HDAC7 Q8WUI4 3/20 0.36
HDAC2 Q92769 3/20 0.36
HDAC10 Q969S8 3/20 0.36
HDAC11 Q96DB2 3/20 0.36
HDAC8 Q9BY41 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
HDAC9 Q9UKV0 3/20 0.36
HDAC5 Q9UQL6 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6135076 1.00 MAPT (0.41) MAPTPTGS2TP53SMN1; SMN2CXCR2
SCHEMBL5882069 0.91 MAPT (0.42) MAPTPTGS2TP53SMN1; SMN2PTPN5
SCHEMBL5882071 0.91 MAPT (0.42) MAPTPTGS2TP53SMN1; SMN2PTPN5
SCHEMBL5881987 0.90 MAPT (0.42) MAPTPTGS2TP53PTPN5KMT2A
SCHEMBL6318588 0.88 SCN5A (0.40) MAPTPTGS2TP53PTPN5MEN1
SCHEMBL6319284 0.88 SCN5A (0.40) MAPTPTGS2TP53PTPN5MEN1
SCHEMBL6322250 0.87 CXCR2 (0.38) MAPTPTGS2TP53SMN1; SMN2CXCR2
SCHEMBL5881737 0.84 SNCA (0.39) MAPTPTGS2TP53PTPN5HDAC1
SCHEMBL5881740 0.84 SNCA (0.39) MAPTPTGS2TP53PTPN5HDAC1
SCHEMBL6298789 0.84 ALDH1A1 (0.35) MAPTSMN1; SMN2MEN1KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050197376-A1 Concomitant drugs FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-09-08 US disclosed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A MAPT 3941/4885PTGS2 2111/4885TP53 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.